In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 288 for your search:

Drug:  fludarabine phosphate
Find trials that include:  Any drugs shown
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL01, NCT00198991

Efficacy of G-CSF-Priming in Elderly AML Patients

Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: AML-elderly 01/99 Trial, NCT00199147

Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors

Phase: Phase IV
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: SCT 0208, NCT00679536

A Study of MabThera (Rituximab) in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia And Favorable Somatic Status

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25136, NCT01271010

A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status

Phase: Phase IV
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25137, NCT01283386

Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS

Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: LAL-AR/2011, NCT01540812

Phase II/III Randomized Study of Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 19 to 70
Sponsor: Other
Protocol IDs: F080429003, UAB-0775, NCT00714259

Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MYFLAI07, NCT00909168

10.

Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia

Phase: Phase III
Type: Treatment
Status: Active
Age: 35 to 55
Sponsor: Other
Protocol IDs: P040420, AOM04088, NCT00224614

11.

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

Phase: Phase III
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: MCL2004-1, NCT00209209

12.

Phase III Study of Fludarabine and Darbepoetin alfa in Geriatric Patients With Chronic Lymphocytic Leukemia and Comorbidities. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Active
Age: Geriatric
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GCLLSG-CLL9, EU-20561, AMGEN-GCLLSG-CLL9, EUDRACT-2005-003014-15, NCT00281892

13.

Phase III Randomized Study of Rituximab, Fludarabine, and Cyclophosphamide Versus Observation Only in Patients With High-Risk, Previously Untreated Binet Stage A B-Cell Chronic Lymphocytic Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GCLLSG-CLL7, EU-20559, ROCHE-GCLLSG-CLL7, EUDRACT-2005-003-018-14, NCT00275054

14.

Phase III Randomized Study of First-Line Therapy Comprising Chlorambucil Versus Fludarabine Phosphate in Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma With Villous Lymphocytes, or Non-IgM Lymphoplasmacytic Lymphoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: TSH-WM1, ISRCTN56052618, TSH-WM1, NCT00608374

15.

Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML

Phase: Phase III
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: AML SCT-BFM 2007, 2007-004517-34, NCT00606723

16.

Phase III Randomized Study of Fludarabine Phosphate and Cyclophosphamide With Versus Without Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CRUK-UCL-MCLIII, CRUK-UCL-MCLIII, EUDRACT-2006-001965-41, MREC-02/6/31, EU-20824, NCT00641095

17.

Fludarabine, Cyclophosphamide, and Rituximab Followed by Rituximab or Observation in Treating Older Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 65
Sponsor: Other
Protocol IDs: CDR0000589684, CHRUT-LLC-2007-SA, CHRUT-PHRN05-CD, INCA-RECF0497, EUDRACT-2007-001015-28, LLC 2007 SA, NCT00645606

18.

Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: WM1, NCT00566332

19.

Phase III Partially Randomized Study of Combination Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 18
Sponsor: Other
Protocol IDs: CCLG-ALLR3, CCLG-ALLR3, ISCRTN-45724312, EUDRACT-2004-000052-16, EU-20938, NCT00967057

20.

Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 60 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000659585, ECOG-E2906, E2906, NCT01041703

21.

Phase III Randomized Study of Standard Induction Chemotherapy With or Without Nelarabine or Rituximab in Patients With Newly Diagnosed, Previously Untreated Acute Lymphoblastic Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 25 to 65
Sponsor: Other
Protocol IDs: UCL-08-0167, UCL/08/0167, EU-21009, EUDRACT-2009-012717-22, UCL-UKALL14, MREC-09-H0711-90, NCRI-UCL-08-0167, CRUK-C27995-A9609, NCT01085617

22.

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia

Phase: Phase III
Type: Treatment
Status: Active
Age: Under 18
Sponsor: Other
Protocol IDs: AIEOP-BFM ALL 2009, NCT01117441

23.

Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior AlloHSCT in AML

Phase: Phase III
Type: Treatment
Status: Active
Age: 40 to 65
Sponsor: Other
Protocol IDs: GITMO AMLR2, NCT01191957

24.

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412

25.

A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients

Phase: Phase III
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: ISRCTN99217456, 2008-004759-31, NCT01303887

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map